Recursion to Acquire Exscientia for $688M in AI-Powered Deal
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
- Latest
- Trending
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Shares of Tripadvisor Inc. surge after forming a special committee to evaluate potential transaction proposals, driving up investor optimism.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.